Currently, Karyopharm Therapeutics Inc [KPTI] is trading at $8.19, down -5.59%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KPTI shares have gain 10.74% over the last week, with a monthly amount glided 26.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Karyopharm Therapeutics Inc [NASDAQ: KPTI] stock has seen the most recent analyst activity on October 13, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $15 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on July 16, 2025. Piper Sandler started tracking the stock assigning an Overweight rating and suggested a price target of $8 on January 19, 2023. RBC Capital Mkts upgraded its rating to an Outperform and raised its price target to $10 on November 04, 2022. JP Morgan upgraded its rating to Neutral for this stock on February 09, 2022, but kept the price target unchanged to $8.
This stock has fluctuated between a low of $3.51 and a high of $11.40 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $14.17 within the next 12 months. Karyopharm Therapeutics Inc [NASDAQ: KPTI] shares were valued at $8.19 at the most recent close of the market. An investor can expect a potential return of 73.02% based on the average KPTI price forecast.
Analyzing the KPTI fundamentals
Trailing Twelve Months sales for Karyopharm Therapeutics Inc [NASDAQ:KPTI] were 142.53M which represents 13.57% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.73%, Pretax Profit Margin comes in at -0.87%, and Net Profit Margin reading is -0.87%. To continue investigating profitability, this company’s Return on Assets is posted at -1.3, Equity is 0.55 and Total Capital is -11.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Karyopharm Therapeutics Inc [NASDAQ:KPTI] is 1.03. As well, the Quick Ratio is 0.98, while the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 1.05.
Transactions by insiders
Recent insider trading involved Abate Kristin, Chief Accounting Officer, that happened on Oct 01 ’25 when 362.0 shares were sold. President and CEO, Paulson Richard A. completed a deal on Sep 15 ’25 to sell 1257.0 shares. Meanwhile, SVP, General Counsel&Secretary Mano Michael sold 234.0 shares on Sep 15 ’25.
